Transitioning Treatment in Diabetic Retinopathy
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Please try again. The questions you answered incorrectly are highlighted in red below.
Correct Answer: C
Rationale: Patients treated with intravitreal aflibercept had significantly greater rates of ≥2-step improvement in DR severity score at 24 and 52 weeks. Intravitreal aflibercept–treated patients had significantly lower rates of vision-threatening complications compared with sham. Patients treated with aflibercept received treatment every 8 or 16 weeks.
Correct Answer: B
Rationale: Patients treated with ranibizumab had superior mean BCVA after 2 years compared with those treated with PRP. Decreased rates of vitrectomy and risk of developing CI-DME were noted.